Pfizer is bankrolling a biotech start-up that will concentrate on developing new stem cell therapies for eye disease. Scripps Research Institute's Martin Friedlander has undertaken animal studies that identified bone and blood-marrow stem cells that could repair damaged blood vessels in the eye. And the new company, EyeCyte, will be responsible for advancing that research into the clinic. Pfizer is investing $3 million in the company and has an option to buy it if continues to look promising.

"Pfizer has put its flag in the ground that there is a future in regenerative medicine," said Pfizer's Corey Goodman.

- read the report [1] from Forbes

Related Articles:
Pfizer blazes new research path with university deal [1]
Pfizer to invest $50M in biotech start-ups [2]
A look inside Pfizer's biotech center [3]
Pfizer hires new R&D chief, launches biotech center [4]